ACP
ATRA icon

Acuta Capital Partners’s Atara Biotherapeutics ATRA Stock Holding History

Acuta Capital Partners’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,800
Closed -$2.51M – 41
2015
Q4 		$2.51M Buy
+3,800
New +$2.87M 1.2% 25

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acuta Capital Partners's ATRA Position: Q1 2016 in Review

Acuta Capital Partners sold out of Atara Biotherapeutics (ATRA) in Q1 2016, closing a stake of 3,800 shares — an estimated $2.51M sold.

Acuta Capital Partners first reported a position in ATRA in Q4 2015 and held it in 1 quarter. The position peaked at $2.51M in Q4 2015. 71 funds tracked by Wall St. Rank hold ATRA as of Q1 2016.

  • Acuta Capital Partners reported no remaining Atara Biotherapeutics position as of Q1 2016 after selling out during the quarter.
  • Acuta Capital Partners sold 3,800 Atara Biotherapeutics shares in Q1 2016, an estimated $2.51M.
  • Acuta Capital Partners first reported a position in Atara Biotherapeutics in Q4 2015 and held it in 1 quarter.
  • Acuta Capital Partners's Atara Biotherapeutics position peaked at $2.51M in Q4 2015.
  • 71 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2016.

Based on Acuta Capital Partners's 13F filing for Q1 2016, filed 13 May 2016.